It looks almost everyone with ovarian cancer should get a PARP inhibitor. In fact, it's looked that way for quite a while, but some oncologists are still resistant to the idea.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”